July 15, 2020
What do you say to parents when they tell you they are concerned because their daughter’s distance vision is blurry again and her eyeglass prescription was updated just six months ago? To help alleviate the concerns of some parents, eye care professionals now can offer a new FDA-approved* solution for their children, aged 8-12 (at initiation of treatment) with myopia.
The CooperVision MiSight® 1 day lens is a daily wear, single-use contact lens that has been clinically proven and FDA-approved* to slow the progression of myopia at the initiation of treatment for children 8-12 years old.1 Until now, traditional eyeglasses and contact lenses available in the U.S. have only been developed to correct nearsightedness.
Watch this video to learn more about how MiSight® 1 day contact lenses positively impacts children’s lives. Three current and former MiSight® 1 day clinical trial participants (who are now all young adults) describe their experiences with the MiSight® 1 day lenses and how wearing the lenses improved their daily activities.
CooperVision’s research into MiSight 1 day’s effectiveness has been far-reaching. This includes the prospective, multi-center, double-masked, randomized multi-year study that enrolled 144 myopic children aged 8-12 years from Singapore, Canada, the United Kingdom, and Portugal, which accounts for the FDA’s approved age range for initial fitting.1 Three-year peer-reviewed results published in Optometry and Vision Science in 2019 indicated that use of MiSight 1 day was shown to slow myopia progression: 59% as measured by mean cycloplegic spherical equivalent refractive error and 52% as measured by mean axial elongation of the eye, when compared to the children in the control group wearing a single vision 1-day contact lens.1
Addressing axial elongation helps to reduce the risk of myopia-related vision complications later in life, including irreversible vision loss. Longer axial length has been linked to sight-threatening conditions later in life, such as retinal detachment, glaucoma, and myopic maculopathy.2 Professor Ian Flitcroft has very clearly articulated that there is no such thing as a “safe” level of myopia, and even low levels of myopia increase the odds of ocular disease compared to emmetropia.3 Generally, myopia first occurs between ages 6 and 12, and 90 percent of myopes stabilize by age 21.4
According to recent research conducted in the U.S., 42 percent of children in a diverse sample ages 5 to 19 have myopia.5 Contributing factors may be due to changing lifestyles, with children spending less time outdoors and more time focusing on close objects such as digital screens.6 Among eye care professionals, 81 percent agree that myopia is one of the biggest problems impacting children’s eyesight today.7
The MiSight 1 day contact lens offers significant advantages to some children with myopia. It has been proven effective in slowing the progression of myopia in children, aged 8-12 at the initiation of treatment, and it is easy for children to wear and handle.1 When placed on the eye, optic zones of the MiSight 1 day contact lens corrects the refractive error to improve distance vision in nearsighted eyes, similar to a standard single vision corrective lens. In addition, concentric rings in the lens focus part of the light in front of the retina. This is believed to reduce the stimulus contributing to the progression of myopia.1
Myopia can no longer be considered a benign refractive error that can be managed by traditional optical means. With the increasing prevalence of myopia and the increased risk of ocular pathology associated with higher levels of myopia, eye care practitioners must monitor and manage children with myopia carefully. With MiSight 1 day, CooperVision can help empower eye care professionals and parents to take on myopia management long term with a proven approach scientifically designed for the challenge.
To learn more about Brilliant Futures™ with MiSight® 1 day, go to https://coopervision.com/practitioner/myopia-management
- Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567. Compared to a single vision 1 day lens over a 3 year period.
- Tideman JW, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363.
- Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622-60.
- COMET Group. (2013). Myopia stabilization and associated factors among participants in the Correction of Myopia Evaluation Trial (COMET). Investigative ophthalmology & visual science, 54(13), 7871.
- Theophanous C et al. Myopia prevalence and risk factors in children. Clin Ophthalmol 2018;12:1581-87.
- Gifford P, Gifford KL. The Future of Myopia Control Contact Lenses. Opt Vis Sci. 2016;93(4):336-343.
- CooperVision data on file 2019. Myopia Awareness, The Harris Poll online survey 6/27/19 to 7/18/19 of n=313 ECPs (who see at least 1/month myopic child, age 8-15) in the U.S.
* Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.